Ikarian Capital, LLC Gemini Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	BUY	$1.29 - $3.08 $28,439 - $67,901	22,046 Added 5.24%	443,096 $615,000
Q3 2021 Nov 15, 2021	SELL	$3.3 - $6.32 $17,836 - $34,159	-5,405 Reduced 1.27%	421,050 $1.7 Million
Q2 2021 Aug 16, 2021	SELL	$6.32 - $14.02 $1.63 Million - $3.62 Million	-257,924 Reduced 37.69%	426,455 $2.76 Million
Q1 2021 May 17, 2021	BUY	$11.32 - $18.0 $7.75 Million - $12.3 Million	684,379 New	684,379 $9.27 Million

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.